HSIC241220C115000
- 0.00
- 0.000.00%
Henry Schein Newsroom
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
Is Henry Schein, Inc. (NASDAQ:HSIC) Potentially Undervalued?
How Is The Market Feeling About Henry Schein?
Henry Schein to Participate at J.P. Morgan's Healthcare Investor Conference
The Returns On Capital At Henry Schein (NASDAQ:HSIC) Don't Inspire Confidence
What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players?
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX), Henry Schein (HSIC) and Geron (GERN)
The Analyst Verdict: Henry Schein In The Eyes Of 4 Experts
Mizuho Initiates Coverage On Henry Schein With Neutral Rating, Announces Price Target of $75
Henry Schein Analyst Ratings
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Unusual Options Activity: WMT, ULTA and Others Attract Market Bets, WMT V/OI Ratio Reaches 440.4
EST Dec 3rd Morning Delivery - In the last two hours of trading, 8 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Henry Schein, Inc.'s (NASDAQ:HSIC) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Biden Proposes Medicare, Medicaid Coverage of Obesity Drugs
Activist Ananym Has a List of Suggestions for Henry Schein. How the Firm Can Help Improve Profits
Henry Schein to Participate in Investor Conferences in December
Hold Rating Maintained for Henry Schein Amid Market Challenges and Activist Investor Influence
Peering Into Henry Schein's Recent Short Interest
Henry Schein To Buy Continuous Glucose Monitors Supplier Acentus
Henry Schein: Acentus Has Annual Revenue of About $35 Million >HSIC